RMIT scientists in Melbourne have led an international collaboration that potentially unlocks better treatment of viral diseases, including the flu and common cold.
The results were published in the prestigious scientific and medical journal Nature Communications.
Each year the flu virus sends 13,500 Australians to hospital and causes more than 3000 deaths among those aged over 50. The global burden is also staggering, with more than 5 million cases of infection annually with up to 10 per cent resulting in death.
The RMIT senior authors, Dr Stavros Selemidis (ARC Future Fellow) and Dr Eunice To (first author), collaborated with Professor Doug Brooks from University South Australia, Professor John O’Leary from Trinity College Dublin, Monash University’s Professor Christopher Porter, and other scientists and clinicians to investigate how viruses cause disease in humans.
The researchers discovered that a 1.5 billion-year-old cell biological process found in plants, fungi and mammals enhances viral disease in mice and highly likely also in humans. They identified a protein, Nox2 oxidase, that is activated by viruses, including influenza, rhinovirus (the common cold), dengue and HIV.
Once activated, Nox2 oxidase suppresses the body’s key antiviral reaction and its ability to fight and clear the viral infection, which in turn results in a stronger or more virulent disease in mice.
The study also investigated a new prototype drug to treat these debilitating viral diseases.
The researchers found that the Nox2 oxidase protein activated by the viruses is located in a cell compartment called endosomes. They carefully modified a chemical that inhibits or restrains the activity of Nox2 oxidase.
Their customised drug was found to be very effective at suppressing disease caused by influenza infection.
Selemidis, head of the Oxidant and Inflammation Biology Group within the Chronic Infectious and Inflammatory Diseases program at RMIT, said: “Current treatment strategies are limited as they specifically target circulating viruses and have either unknown or very little effect against new viruses that enter the human population.
“We have identified a protein of the immune system that contributes to the disease caused by flu viruses irrespective of their strain.
“We also developed a novel drug delivery system to target this protein, which drastically alleviated the burden of viral disease.
“The strength of this work is the multidisciplinary approach taken and the degree of collaboration. It includes researchers and clinicians from eight universities across Australia, the United States and Ireland.
“This work attracted considerable interest at the NADPH Oxidase GORDON conference in the USA last year.”
To said: “This work identifies a treatment strategy that has the potential to alleviate the symptoms caused by some of the most devastating viruses worldwide, including the flu.”
The Latest on: Viral diseases
- Koala Genes Are Being Attacked By A Virus, But Their DNA Is Fighting Backon October 13, 2019 at 9:11 pm
These viral sequences can contribute to disease, but have also been “co-opted” by the host animals for processes that are essential to normal development. As much as 8 per cent of the human genome is ...
- Drug reverses signs of liver disease in people living with HIVon October 12, 2019 at 11:38 am
The study was conducted by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute, both parts of NIH. The findings were published online today in The ...
- Flesh-eating ulcer's spread to new part of Australia worries infectious disease expertson October 11, 2019 at 10:13 pm
The spread of a severe tissue-destroying ulcer once rare in Australia to a new geographic area in Queensland has infectious disease experts worried. The Buruli ulcer, also known as the Bairnsdale ...
- 2019 Automated Microbiology Market Report in India - Based on over 100 Infectious Disease Tests - ResearchAndMarkets.comon October 11, 2019 at 5:05 pm
This new report from the author examines current and emerging assays; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine ...
- Shares of Gates-backed Vir Bio tumble after $143M IPO to fund infectious disease effortson October 11, 2019 at 3:59 pm
It was a rough Wall Street debut for Vir Biotechnology, a San Francisco company with ambitious plans to battle infectious diseases. After raising $143 million in an initial public offering on Thursday ...
- Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officeron October 11, 2019 at 2:49 am
Dr. Mendelman replaces Dr. Wolfgang Dummer who has departed the company for personal reasons. "It is a pleasure to welcome Dr. Mendelman, a recognized leader in the development of new treatments for ...
- Analysis on the Global Market for Infectious Disease Diagnostics, 2018-2019 and Forecast to 2026on October 11, 2019 at 2:10 am
Dublin, Oct. 11, 2019 (GLOBE NEWSWIRE) -- The "Infectious Disease Diagnostics: World Market Analysis: HIV/AIDS, Hepatitis, Tuberculosis, STDs, HAIs, ID/AST, Influenza, TORCH, Other" report has been ...
- New bioinformatics hub at UChicago enables next-gen infectious disease researchon October 11, 2019 at 12:07 am
The most valuable weapon against the next deadly disease outbreak may be data. Scientists aiming to stop or prevent the spread of viral or bacterial pathogens need rapid, comprehensive access to ...
- Infectious disease in marine life linked to decades of ocean warmingon October 10, 2019 at 7:41 am
"The long-term changes in disease that we see here may result from anthropogenic pressure on plants and animals in the ocean." The researchers examined marine infectious disease reports from 1970 to ...
- Never shy from infectious-disease mysterieson October 10, 2019 at 6:37 am
Patrícia Brasil is head of the Laboratory of Acute Febrile Illness of the National Institute of Infectious Diseases Evandro Chagas, Fiocruz, and professor of tropical medicine and clinical research in ...
via Google News and Bing News